125 related articles for article (PubMed ID: 23974730)
21. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
[TBL] [Abstract][Full Text] [Related]
22. [Current results on PSA-based prostate cancer detection].
Graefen M; Schlomm T; Steuber T; Sauter G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Mar; 57(3):312-7. PubMed ID: 24562706
[TBL] [Abstract][Full Text] [Related]
23. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.
Catalona WJ; Smith DS; Ratliff TL; Dodds KM; Coplen DE; Yuan JJ; Petros JA; Andriole GL
N Engl J Med; 1991 Apr; 324(17):1156-61. PubMed ID: 1707140
[TBL] [Abstract][Full Text] [Related]
24. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
25. Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?
Bantis A; Grammaticos P
Hell J Nucl Med; 2012; 15(3):241-6. PubMed ID: 23227460
[TBL] [Abstract][Full Text] [Related]
26. Prognosis: Proportionate response.
DeWeerdt S
Nature; 2015 Dec; 528(7582):S124-5. PubMed ID: 26672783
[No Abstract] [Full Text] [Related]
27. Serum prostate-specific antigen: the most useful tumor marker.
Andriole GL
J Clin Oncol; 1992 Aug; 10(8):1205-7. PubMed ID: 1378885
[No Abstract] [Full Text] [Related]
28. Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program.
Rubio-Briones J; Casanova J; Dumont R; Rubio L; Fernandez-Serra A; Casanova-Salas I; Domínguez-Escrig J; Ramírez-Backhaus M; Collado A; Gómez-Ferrer A; Iborra I; Monrós JL; Ricós JV; Solsona E; Salas D; Martínez F; Lopez-Guerrero JA
Actas Urol Esp; 2014 May; 38(4):217-23. PubMed ID: 24169211
[TBL] [Abstract][Full Text] [Related]
29. Patient knowledge about prostate-specific antigen (PSA) and prostate cancer in Australia.
Pan D; McCahy P
BJU Int; 2012 Apr; 109 Suppl 3():52-6. PubMed ID: 22458495
[TBL] [Abstract][Full Text] [Related]
30. Pathology consultation on prostate-specific antigen testing.
Noguez JH; Fantz CR
Am J Clin Pathol; 2014 Jul; 142(1):7-15. PubMed ID: 24926079
[TBL] [Abstract][Full Text] [Related]
31. A reliable coding system to define screening prostate-specific antigen tests was developed in a case-control study.
Bunting PS; Neuman J; Goel V; Fleshner N; Kopec J; Levers P; Warde P
J Clin Epidemiol; 2005 Jun; 58(6):639-44. PubMed ID: 15878478
[TBL] [Abstract][Full Text] [Related]
32. PSA in screening for prostate cancer: more good than harm or more harm than good?
Duffy MJ
Adv Clin Chem; 2014; 66():1-23. PubMed ID: 25344984
[TBL] [Abstract][Full Text] [Related]
33. Advances in proteomic prostate cancer biomarker discovery.
Goo YA; Goodlett DR
J Proteomics; 2010 Sep; 73(10):1839-50. PubMed ID: 20398807
[TBL] [Abstract][Full Text] [Related]
34. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
35. [Non- PSA serum markers for the diagnosis of PCa].
Mengual L; Musquera M; Ciudin A; Ribal MJ
Arch Esp Urol; 2015 Apr; 68(3):229-39. PubMed ID: 25948796
[TBL] [Abstract][Full Text] [Related]
36. uPM3, a new molecular urine test for the detection of prostate cancer.
Fradet Y; Saad F; Aprikian A; Dessureault J; Elhilali M; Trudel C; Mâsse B; Piché L; Chypre C
Urology; 2004 Aug; 64(2):311-5; discussion 315-6. PubMed ID: 15302485
[TBL] [Abstract][Full Text] [Related]
37. Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer.
Lucarelli G; Rutigliano M; Bettocchi C; Palazzo S; Vavallo A; Galleggiante V; Trabucco S; Di Clemente D; Selvaggi FP; Battaglia M; Ditonno P
J Urol; 2013 Dec; 190(6):2271-7. PubMed ID: 23665271
[TBL] [Abstract][Full Text] [Related]
38. Innovative biomarkers for prostate cancer early diagnosis and progression.
You J; Cozzi P; Walsh B; Willcox M; Kearsley J; Russell P; Li Y
Crit Rev Oncol Hematol; 2010 Jan; 73(1):10-22. PubMed ID: 19328712
[TBL] [Abstract][Full Text] [Related]
39. An evaluation of prostate-specific antigen as a screening test for prostate cancer.
Dorr VJ; Williamson SK; Stephens RL
Arch Intern Med; 1993 Nov; 153(22):2529-37. PubMed ID: 7694555
[TBL] [Abstract][Full Text] [Related]
40. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
